FDA Authorizes Abbott’s '$5, 15 Minute' COVID-19 Antigen Test
The BinaxNOW COVID-19 Ag Card portable lateral flow test, which delivers rapid results with no instrumentation, could be a “game changer” in the effort to reopen schools and other crowded places.
You may also be interested in...
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
The annual J.P. Morgan Healthcare Conference includes presentations from many major medtech companies outlining their growth strategies and expectations for 2021. Here are some of the highlights from the second day of the meeting.
Abbott plans to deliver 30 million BinaxNOW prescription, at-home rapid tests in the first quarter of 2021; 90 million more in the second quarter.